Pangaea Oncology provides Molecular Diagnostics and R+D services in the field of personalized cancer treatment. Our research programs include Biomarker Discovery, Molecular Diagnostics Assays and Drug Development. Founded in 2007, we have grown rapidly to become a reference laboratory in our field and and have established client relationships with some of the largest global pharmaceutical, diagnostics and biotech companies.
Our mission is to generate a new framework of therapeutic oncology based on personalized models, and incorporate this strategy into standard medical practice.
For patient care, we are the molecular diagnostics laboratory of choice for the Dr Rosell Oncology Institute (IOR) and the reference laboratory for cancer testing for the Quirón Dexeus University Hospital, Barcelona. Through these partnerships we gain valuable insights which inform our R+D programs.
Our Chief Scientific Officer is international expert in translational cancer research Dr Rafael Rosell, and our Pathology Unit is led by renowned expert pathologist Dr Santiago Ramon y Cajal. The Pangaea team is composed of prestigious clinical and research professionals, combining expertise in preclinical cancer research with extensive experience in biomarker discovery, drug development and diagnostic tools with a special focus on liquid biopsies.
For certain cancers, we have developed highly sensitive and specific diagnostic tests using alternative biosources such as blood. This overcomes the challenges associated with obtaining sufficient tumor material for genetic analyses and makes serial treatment monitoring and early detection of therapy resistance a reality in personalized cancer treatment. We are one of the leading European providers in the field of liquid biopsies and the first pharmacogenomics laboratory in Spain to be accredited, by the National Accreditation Body (ENAC), ISO 15189, to perform genetic testing for cancer patients in liquid biopsy (serum/plasma) samples (EGFR mutations, exon 19, 20 [T790M] and 21; KRAS, exon 12-13; BRAF V600E) (nº750 / LE15156 Annex 7).
In-house and through partnerships we perform comprehensive pathology, molecular biology, in vitro and in vivo techniques:
Mutation analysis in tumor tissue and blood
Gene amplification and translocation testing
MTT proliferation assays
Colony formation, migration and invasion assays
Molecular profiling of cell lines and tissue samples
We have the capacity to work with formalin-fixed paraffin-embedded tumor tissue, fresh frozen samples, serum, plasma, platelets, and cytologies.
We perform pathological evaluation of tumors via bright field to confirm diagnoses. Our highly accurate microdissection equipment enables dissection of specific cells, ensuring maximum efficiency in subsequent tests.
Clinical Molecular Diagnostics Services
Pangaea Oncology SA has not received any reviews.
Pangaea Oncology SA has not received any endorsements.